US 12,263,206 B2
Pharmaceutical composition for preventing or treating obesity or sarcopenia, containing IF1 as active ingredient
Min-Jeong Shin, Seoul (KR); Hyeon Soo Kim, Seoul (KR); and Ji Hyung Chung, Seoul (KR)
Assigned to Medi&Gene Inc., Seoul (KR)
Appl. No. 17/276,212
Filed by Medi&Gene Inc., Seoul (KR)
PCT Filed Sep. 11, 2019, PCT No. PCT/KR2019/011865
§ 371(c)(1), (2) Date Mar. 15, 2021,
PCT Pub. No. WO2020/055186, PCT Pub. Date Mar. 19, 2020.
Claims priority of application No. 10-2018-0110413 (KR), filed on Sep. 14, 2018; and application No. 10-2018-0117692 (KR), filed on Oct. 2, 2018.
Prior Publication US 2022/0023393 A1, Jan. 27, 2022
Int. Cl. A61K 38/17 (2006.01); A61K 38/00 (2006.01); A61K 38/43 (2006.01); A61P 3/04 (2006.01); A61P 21/00 (2006.01)
CPC A61K 38/43 (2013.01) [A61K 38/005 (2013.01); A61P 3/04 (2018.01); A61P 21/00 (2018.01)] 9 Claims
 
1. A method for alleviating or treating obesity comprising administering recombinant exogenous ATPase inhibitory factor 1 (IF1) as an active ingredient to a subject in need thereof,
wherein the recombinant exogenous IF1 consists of the amino acid sequence of SEQ ID NO: 1.